Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 9:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 58 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: mirabegron Clear all
Withdrawn Not applicable Interventional

Comparison of Electroacupuncture to Mirabegron for Treatment of Overactive Bladder

NCT03087578
View directory record Official record
Conditions
Overactive Bladder
Interventions
electroacupncture, Mirabegron 50 MG [Myrbetriq]
Other · Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Sep 7, 2026, 9:38 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

ADRB3 Signaling Pathway in Human Adipose Tissue

NCT05634174
View directory record Official record
Conditions
Obesity, Prediabetes
Interventions
Mirabegron
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Sep 7, 2026, 9:38 AM EDT
Completed Phase 2 Interventional Results available

The Effects of Normalizing Blood Pressure on Cerebral Blood Flow in Hypotensive Individuals With Spinal Cord Injury

NCT02893553
View directory record Official record
Conditions
Spinal Cord Injury, Autonomic Dysreflexia, Baroreceptor Integrity, Sympathetic Integrity, Vagal Integrity, Autonomic Integrity, Hypotensive, Cognitive Function, Cerebral Blood Flow, Blood Pressure
Interventions
Midodrine Hydrochloride, Pyridostigmine Bromide, Mirabegron, Placebo
Drug · Other
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 85 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
West Orange, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Sep 7, 2026, 9:38 AM EDT
Withdrawn Phase 4 Interventional

Mirabegron for the Treatment of Pain Motivated Urinary Frequency and Urgency in Women

NCT02981459
View directory record Official record
Conditions
Urinary Frequency/Urgency, Bladder Irritable, Bladder Pain Syndrome
Interventions
Mirabegron
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 89 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 7, 2026, 9:38 AM EDT
Completed Phase 4 Interventional Results available

Study of Behavioral Modification Program and Mirabegron to Improve Urinary Urgency in Multiple Sclerosis

NCT02086188
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Mirabegron, Placebo
Drug
Lead sponsor
Theodore R. Brown, MD MPH
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Sep 7, 2026, 9:38 AM EDT
Completed Phase 3 Interventional Results available

Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

NCT00688688
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
Mirabegron, Tolterodine, Placebo to Mirabegron, Placebo to Tolterodine
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
2,792 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
106
States / cities
Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 96 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Sep 7, 2026, 9:38 AM EDT
Completed Phase 2 Interventional Results available

Using Mirabegron to Increase BP in Patients With POTS

NCT06133075
View directory record Official record
Conditions
Postural Orthostatic Tachycardia Syndrome, Chronic Orthostatic Intolerance, Syncope
Interventions
Mirabegron 50 MG, Mirabegron 25 MG
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Sep 7, 2026, 9:38 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Mechanisms for Activation of Beige Adipose Tissue in Humans

NCT04666636
View directory record Official record
Conditions
PreDiabetes
Interventions
Placebo, Mirabegron, Mirabegron 50 MG, Mirabegron 100 mg
Drug
Lead sponsor
Philip Kern
Other
Eligibility
35 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 7, 2026, 9:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Effect of Food on the Pharmacokinetics of Mirabegron

NCT00939757
View directory record Official record
Conditions
Healthy, Pharmacokinetics of Mirabegron
Interventions
mirabegron
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced Sep 7, 2026, 9:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Interaction Study to Assess the Effect of Repeat Doses of Rifampin on Mirabegron (YM178) in Healthy Volunteers

NCT00776516
View directory record Official record
Conditions
Pharmacokinetics of YM178
Interventions
mirabegron, rifampin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 2, 2013 · Synced Sep 7, 2026, 9:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Intraocular Pressure and Ocular Safety of the Beta-3 Agonist Mirabegron in Research Subjects

NCT01284309
View directory record Official record
Conditions
Intraocular Pressure
Interventions
Mirabegron, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
321 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 10, 2013 · Synced Sep 7, 2026, 9:38 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Treatment of Incontinence Without Memory Problems

NCT02436889
View directory record Official record
Conditions
Urge Incontinence, Urinary Incontinence, Urge
Interventions
Mirabegron, Tolterodine Tartrate
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
65 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Sep 7, 2026, 9:38 AM EDT
Not yet recruiting Phase 4 Interventional

Pilot Deprescribing of Antimuscarinic Overactive Bladder Medications in Parkinson Disease

NCT07627529
View directory record Official record
Conditions
Parkinson Disease (PD)
Interventions
Overactive bladder antimuscarinic deprescribing
Drug
Lead sponsor
Corporal Michael J. Crescenz VA Medical Center
Federal
Eligibility
60 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 7, 2026, 9:38 AM EDT
Completed No phase listed Observational

A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)

NCT02386072
View directory record Official record
Conditions
Urinary Bladder Overactive, Overactive Bladder, Urinary Bladder Diseases, Urologic Diseases
Interventions
mirabegron, antimuscarinic medication
Drug
Lead sponsor
Astellas Scientific & Medical Affairs, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
75
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 56 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Sep 7, 2026, 9:38 AM EDT
Completed Phase 2 Interventional Results available

Mirabegron as Medical Expulsive Therapy (MET) for Ureteral Stones and Ureteral Stent Pain

NCT02744430
View directory record Official record
Conditions
Ureteral Obstruction, Flank Pain
Interventions
Mirabegron, Placebo
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Sep 7, 2026, 9:38 AM EDT
Active, not recruiting Phase 4 Interventional

Effect of Behavioral Sleep Intervention on Lower Urinary Tract Symptoms in Older Women

NCT05604222
View directory record Official record
Conditions
Urgency Urinary Incontinence, Nocturia
Interventions
Mirabegron 50 MG, Brief Behavioral Treatment for Insomnia
Drug · Behavioral
Lead sponsor
Shachi Tyagi
Other
Eligibility
60 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 7, 2026, 9:38 AM EDT
Completed Phase 3 Interventional Results available

A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder

NCT02045862
View directory record Official record
Conditions
Urinary Bladder Overactive, Overactive Bladder, Urgency Incontinence, Urinary Bladder Diseases\Urologic Diseases
Interventions
Solifenacin succinate, Mirabegron, Placebo to match solifenacin, Placebo to match mirabegron
Drug
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Eligibility
18 Years and older
Enrollment
1,829 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
75
States / cities
Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Sep 7, 2026, 9:38 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics

NCT05051436
View directory record Official record
Conditions
Pre-diabetes, Obesity
Interventions
Mirabegron 50 MG, Tadalafil 10 MG, Placebo
Drug
Lead sponsor
Philip Kern
Other
Eligibility
35 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 7, 2026, 9:38 AM EDT
Completed No phase listed Observational

Myrbetriq™ (Mirabegron) to Improve Disordered Sleep in Subjects With Lower Urinary Tract Symptoms (LUTS)

NCT02410135
View directory record Official record
Conditions
Lower Urinary Tract Symptoms, Nocturia
Interventions
Mirabegron
Drug
Lead sponsor
Southern Illinois University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Sep 7, 2026, 9:38 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)

NCT02757768
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Overactive Bladder
Interventions
Mirabegron, Placebo, Tamsulosin Hydrochloride
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
40 Years and older · Male only
Enrollment
715 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
32
States / cities
Homewood, Alabama • Huntsville, Alabama • Anchorage, Alaska + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 7, 2026, 9:38 AM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity

NCT05713799
View directory record Official record
Conditions
Insulin Resistance, Obesity
Interventions
Alpha-lipoic acid, Mirabegron, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 7, 2026, 9:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Oral Mirabegron on the Heart in Healthy Males and Females

NCT01199523
View directory record Official record
Conditions
Healthy Subjects
Interventions
Placebo, mirabegron, moxifloxacin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
352 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2013 · Synced Sep 7, 2026, 9:38 AM EDT
Terminated Early Phase 1 Interventional

Mirabegron in Achalasia: A Clinical and Manometric Proof of Concept Pilot Study

NCT03411252
View directory record Official record
Conditions
Achalasia
Interventions
Mirabegron 50 MG, Placebo
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Sep 7, 2026, 9:38 AM EDT
Completed Phase 3 Interventional Results available

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)

NCT01908829
View directory record Official record
Conditions
Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases
Interventions
mirabegron 25 mg, mirabegron 50 mg, solifenacin 5 mg, solifenacin 10 mg, mirabegron 25 mg matching placebo, mirabegron 50 mg matching placebo, solifenacin 5 mg matching placebo, solifenacin 10 mg matching placebo
Drug
Lead sponsor
Astellas Pharma Europe Ltd.
Industry
Eligibility
18 Years and older
Enrollment
2,174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
36
States / cities
Tucson, Arizona • Buena Park, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Sep 7, 2026, 9:38 AM EDT